CD86 (CTLA-4 / B7-2) Recombinant eiwit, menselijk

The human CD86 (CTLA-4 Counter-Receptor B7-2) is a recombinant protein consisting of a single glycosylated polypeptide chain with 223 amino acids (31-247aa) . CD86 (B7-2) and CD80 (B7-1) are molecules upregulated on Antigen Presenting Cells (APCs) upon activation of Toll-Like Receptor (TLR) pathways, playing a crucial role in T cell activation by binding to the co-stimulatory molecule CD28. CTLA-4 (CD152) is expressed on activated T cells and binds to CD80 and CD86 with higher affinity than CD28, leading to the suppression of T cell activation. Blocking CTLA-4 signaling prolongs T cell activation and enhances anti-tumor responses. CTLA-4 was the first immune checkpoint targeted for cancer treatment. Abbreviations: BU63, B7-2/CD86, B7.2, CD28LG2, B70, CTLA-4 counter-receptor B7.2, CD86, T-lymphocyte activation antigen CD86, LAB72, Activation B7-2 antigen.

The human CD86 (CTLA-4 Counter-Receptor B7-2) is a recombinant protein consisting of a single glycosylated polypeptide chain with 223 amino acids (31-247aa) . CD86 (B7-2) and CD80 (B7-1) are molecules upregulated on...

CD86 (CTLA-4 / B7-2) Recombinant Protein, Human, 20ug

20μg / vial

Cell Signaling Pathways

0.5 mg/mL (Refer to the vial label for the concentration.)

> 95%, as determined by SDS-PAGE

Soluble

This protein is supplied in PBS (pH 7.4) and 10% glycerol.

25.6kDa

Stable at 4°C for one month or stored in the dark at -20°C long-term.

SF9